Closed-loop RNS System reduces seizures by over 75% in 9-year open-label extension

Summary

NeuroPace published 9-year open-label extension data from their RNS System pivotal trial showing median seizure reduction of 75% at 9 years in 256 drug-resistant epilepsy patients, with 35% of patients achieving 90%+ seizure reduction. Serious adverse events were rare and largely device-related rather than stimulation-related.